Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630316 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
A Phase 2 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT02630316 is a Phase 2 study that has completed, run by United Therapeutics. The registered enrollment target is 326 participants.
The verdict
NCT02630316, a Phase 2 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included 326 patients at approximately 120 clinical trial centers. The treatment phase of the study lasted approximately 16 weeks. Patients who completed all required assessments were eligible to enter an open-label, extension study (RIN-PH-202).
Interventions
- DRUG Placebo
- DRUG Inhaled Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2019-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630316
The ClinicalTrials.gov registry entry for NCT02630316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02630316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630316 about?
NCT02630316 is a clinical study titled "Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE". This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined p...
What is the current status of trial NCT02630316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2017-02-03. Estimated completion is 2019-12-26.
What interventions are being tested in trial NCT02630316?
The interventions under investigation include: Placebo (DRUG), Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT02630316?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.